1Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metaboliam from fatty acid oxidation to glucose oxidation by inhibiting mitochondral long- chain 3 - ketoacyl coenzyme a thiolase[J]. Circ Res, 2000,86:580 - 588.
2Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart (abstr)[J] .J Mol Cell Cardiol, 1998,30:A112.
3Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versue coronary angioplasty in diabetic patients with multivessel coronary artery disease[J] .J Am Coll Cardiol, 1998,31 : 10 - 19.
4Allibardi S, Oaierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts [ J ].Cardiovasc Drugs Ther, 1998,12:543 - 549.
5Lu C,Dabrwski P,Fragasso G, et al .Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease[J].Am J Cardlol, 1998,82:8989 - 8901.
6Szwed H, Sadowski Z, Pachocki R, et al. Efficacy and safety of trimetazidine in patients with persistent stable angina pectoris under beta-blocker therapy:TRLMPOL Ⅱ multicentre study[J]. Eur Heart J,1999,20: Abstract No.2516.
7Szwed H, Sadowski X, Pactocki R, et al. Anti - ischemic efficacy and tolerability of trimetazidine in elderly patients with angina pectoris[J].Clin Drugs Invest, 2000,19: L1 - 98.
8Rona G，Arch Pathol，1959年，67卷，4期，443页
9Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischemic cardiomyopathy. Eur Heart J Supplements,2001,3 ( Suppl 0) : 02-07.
10Kantor PF, Lucien A, Kozak R, et aL The anfianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000, 86:580-588.
